Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Generac (GNRC) upgraded to Outperform from Perform at Oppenheimer analyst Christopher Glynn saying he sees "solid" prospects for revenue upside and improving visibility to long-term scaling. 2. BioMarin (BMRN) upgraded to Outperform from Sector Perform at RBC Capital with analyst Kennen Mackay saying he believes that the stock is undervalued ahead of the regulatory decisions on ValRox and the possibility of the company's first "product genericization." 3. STMicroelectronics (STM) upgraded to Neutral from Underperform at Baird with analyst Tristan Gerra saying the current semiconductor cycle trough is "much shallower" than previously expected. 4. DaVita (DVA) upgraded to Buy from Neutral at Goldman Sachs with analyst Stephen Tanal saying beginning in 2021, people with end stage renal disease will be able to enroll in any Medicare Advantage plan, marking a rule change that carries implications across the healthcare services ecosystem. 5. Unilever (UN, UL) upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.